Drug Profile
KADT F10
Alternative Names: KADT-F10Latest Information Update: 20 Mar 2007
Price :
$50
*
At a glance
- Originator Photochemical Company
- Class Porphyrins; Radiosensitisers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Nov 2003 KADT F10 is available for licensing (http://www.optic.or.jp/com/pcc/pcc_e.html)
- 03 Nov 2003 Preclinical trials in Cancer in Japan (unspecified route)